Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
Sarzani
Riccardo
R
Dessì-Fulgheri
Paolo
P
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage* / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control*; D012107:Research Design; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D014633:Valine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068756:Valsartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine